Carlyle Trims Nature's Bounty Assets: Private Equity Rolls In Supplement Space
This article was originally published in The Rose Sheet
Carlyle's $2.2bn sale of Nature's Bounty's Holland & Barrett business to a Russian investment fund is the latest sign of the private equity sector's continuing interest in the health and wellness space.
You may also be interested in...
Since acquiring Nature's Bounty in 2010 and taking the publicly traded firm private, Carlyle could have been at the helm longer than executives at the private equity firm intended or expected, exceeding the five-year plan typical for similar investments.
The firm owned since 2010 by a Carlyle Group holding company opts for a name that encompasses its largest brand, which also had been its name until the previous management chose the name NBTY in 1995.
The Vitamin World deal jettisons one of NBTY's slower-performing businesses after the firm previously began exiting the low-margin contract manufacturing sector. The acquisition by a Centre Lane Partners unit is the second private equity move in the supplement space in two weeks.